Harnessing the Value of ctDNA in Cancer Drug Development
Time: 11:20 am
day: Day One
Details:
- Exploring the developments required for ctDNA to replace traditional tumor biopsies for monitoring treatment response and drug resistance in preclinical trials
- How can ctDNA be leveraged to identify promising drug candidates early in translational development, informing go/no-go decisions for new therapies?
- Considering the potential for ctDNA-guided patient stratification in translational studies, what are the ethical considerations and regulatory hurdles that need to be addressed?
